Dr. Jason Sicklick Receives Grant for Temozolomide Phase II Trial
The Phase One Foundation has awarded GIST Specialist Jason Sicklick a $500,000 grant to study GIST in a Temozolomide Phase II clinical trial.
LRG Webcast Series: Updates on the Temozolomide Trial
Dr. Jason Sicklick of Moores Cancer Center at the University of California San Diego talks about the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.